Anatomical Regions, Introduction

Codes in table XW0

Every code is billable. The 7 characters spell out section, body system, operation, body part, approach, device and qualifier.

• XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
• XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
• XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
• XW0134CIntroduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
• XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
• XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
• XW013G6Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013L9Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
• XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
• XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013TBIntroduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
• XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
• XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
• XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
• XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
• XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
• XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
• XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
• XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
• XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
• XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
• XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
• XW03308Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0330BIntroduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW0333AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW0334AIntroduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW03357Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW03358Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0335AIntroduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0336CIntroduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
• XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
• XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0337CIntroduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
• XW03388Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0338AIntroduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW03396Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW03398Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
• XW0339AIntroduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
• XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033E5Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
• XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033FBIntroduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033K7Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033K9Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
• XW033L6Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
• XW033L7Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
• XW033NAIntroduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
• XW033P9Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
• XW033PBIntroduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033Q9Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
• XW033QBIntroduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW033R9Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
• XW033RBIntroduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033WBIntroduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
• XW04308Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
• XW0430BIntroduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11
• XW0431BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11
• XW0433AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
• XW0434AIntroduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
• XW04357Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
• XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
• XW0435AIntroduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
• XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
• XW0436CIntroduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12
• XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
• XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
• XW04388Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
• XW0438AIntroduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
• XW04396Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
• XW04398Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
• XW0439AIntroduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043A7Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
• XW043BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043CAIntroduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043E5Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043F3Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
• XW043F5Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043FBIntroduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
• XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
• XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
• XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043K7Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043K9Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
• XW043L6Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
• XW043L7Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
• XW043NAIntroduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
• XW043P9Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
• XW043PBIntroduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
• XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043Q9Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
• XW043QBIntroduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
• XW043R9Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
• XW043RBIntroduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
• XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043WBIntroduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
• XW0534BIntroduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11
• XW053T9Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9
• XW0632BIntroduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11
• XW0DX38Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
• XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
• XW0DXF5Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
• XW0DXJ9Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9
• XW0DXK8Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8
• XW0DXM6Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
• XW0DXN9Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9
• XW0DXVBIntroduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11
• XW0E33BIntroduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11
• XW0G738Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
• XW0G7K8Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
• XW0G7M6Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
• XW0G886Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
• XW0H738Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
• XW0H7K8Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
• XW0H7M6Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
• XW0H7X8Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
• XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
• XW0J3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
• XW0J3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
• XW0J3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
• XW0J3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
• XW0K3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
• XW0K3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
• XW0K3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
• XW0K3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
• XW0L3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
• XW0L3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
• XW0L3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
• XW0L3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
• XW0M3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
• XW0M3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
• XW0M3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
• XW0M3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
• XW0Q316Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6
• XW0Q35CIntroduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12
• XW0U0CCIntroduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12
• XW0U0GAIntroduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10
• XW0U0XBIntroduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11
• XW0U3XBIntroduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11
• XW0U4XBIntroduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11
• XW0V0BCIntroduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12
• XW0V0P7Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
• XW0V3WAIntroduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10